Circ_0056285 Regulates Proliferation, Apoptosis and Glycolysis of Osteosarcoma Cells via miR-1244/TRIM44 Axis.
TRIM44
circ_0056285
miR-1244
osteosarcoma
progression
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
11
2020
accepted:
13
01
2021
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
20
2
2021
Statut:
epublish
Résumé
Osteosarcoma (OS) is a common malignant bone cancer that occurs in adolescents and children. Circular RNAs (circRNAs) are important regulators of tumorigenesis and development. This study aimed to explore the role and molecular basis of circ_0056285 in OS. The levels of circ_0056285, miR-1244 and tripartite motif containing 44 (TRIM44) were determined by quantitative real-time polymerase chain reaction or Western blot assay. Cell proliferation was evaluated by Cell Counting Kit-8 (CCK-8) assay and colony formation assay. Cell apoptosis was assessed by flow cytometry and caspase 3and caspase 9 activity assay kits. Glucose uptake, lactate product and ATP level were examined using commercial kits. Hexokinase II (HK2) and lactate dehydrogenase A (LDHA) levels were measured by Western blot assay. The interaction among circ_0056285, miR-1244 and TRIM44 was confirmed by dual-luciferase reporter assay, RNA immunoprecipitation assay or RNA pull-down assay. Xenograft experiment was conducted to explore tumor growth in vivo. Exosomes were identified by transmission electron microscope (TEM), nanoparticle tracking analysis (NTA) and Western blot. The diagnostic value of exosomal circ_0056285 was evaluated by receiver operating characteristic (ROC) curve. Circ_0056285 and TRIM44 were up-regulated, and miR-1244 was down-regulated in OS tissues and cells. Circ_0056285 silencing inhibited proliferation and glycolysis and promoted apoptosis in OS cells. Also, circ_0056285 knockdown hindered proliferation and accelerated apoptosis in OS cells by regulating miR-1244/TRIM44 axis. Circ_0056285 depletion impeded tumor growth in vivo. Furthermore, ROC curve showed that circ_0056285 might be a diagnostic biomarker in OS. Circ_0056285 facilitated OS progression by sponging miR-1244 and increasing TRIM44 expression, providing a promising therapeutic target for OS.
Sections du résumé
BACKGROUND
BACKGROUND
Osteosarcoma (OS) is a common malignant bone cancer that occurs in adolescents and children. Circular RNAs (circRNAs) are important regulators of tumorigenesis and development. This study aimed to explore the role and molecular basis of circ_0056285 in OS.
METHODS
METHODS
The levels of circ_0056285, miR-1244 and tripartite motif containing 44 (TRIM44) were determined by quantitative real-time polymerase chain reaction or Western blot assay. Cell proliferation was evaluated by Cell Counting Kit-8 (CCK-8) assay and colony formation assay. Cell apoptosis was assessed by flow cytometry and caspase 3and caspase 9 activity assay kits. Glucose uptake, lactate product and ATP level were examined using commercial kits. Hexokinase II (HK2) and lactate dehydrogenase A (LDHA) levels were measured by Western blot assay. The interaction among circ_0056285, miR-1244 and TRIM44 was confirmed by dual-luciferase reporter assay, RNA immunoprecipitation assay or RNA pull-down assay. Xenograft experiment was conducted to explore tumor growth in vivo. Exosomes were identified by transmission electron microscope (TEM), nanoparticle tracking analysis (NTA) and Western blot. The diagnostic value of exosomal circ_0056285 was evaluated by receiver operating characteristic (ROC) curve.
RESULTS
RESULTS
Circ_0056285 and TRIM44 were up-regulated, and miR-1244 was down-regulated in OS tissues and cells. Circ_0056285 silencing inhibited proliferation and glycolysis and promoted apoptosis in OS cells. Also, circ_0056285 knockdown hindered proliferation and accelerated apoptosis in OS cells by regulating miR-1244/TRIM44 axis. Circ_0056285 depletion impeded tumor growth in vivo. Furthermore, ROC curve showed that circ_0056285 might be a diagnostic biomarker in OS.
CONCLUSION
CONCLUSIONS
Circ_0056285 facilitated OS progression by sponging miR-1244 and increasing TRIM44 expression, providing a promising therapeutic target for OS.
Identifiants
pubmed: 33603471
doi: 10.2147/CMAR.S290645
pii: 290645
pmc: PMC7882461
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1257-1270Informations de copyright
© 2021 Huo and Dou.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Cancer Med. 2020 Apr;9(8):2833-2845
pubmed: 32064777
J Cell Physiol. 2019 Nov;234(11):19130-19140
pubmed: 31187488
Med Sci Monit. 2018 Oct 04;24:7043-7050
pubmed: 30282962
Cancer Treat Rev. 2014 May;40(4):523-32
pubmed: 24345772
Molecules. 2017 Mar 07;22(3):
pubmed: 28272374
Cell Mol Life Sci. 2019 Dec;76(23):4613-4633
pubmed: 31352532
Exp Ther Med. 2018 Oct;16(4):3034-3040
pubmed: 30214522
J Exp Clin Cancer Res. 2019 Mar 28;38(1):137
pubmed: 30922374
Mol Cell Biochem. 2020 Jan;464(1-2):39-50
pubmed: 31691157
Oncol Rep. 2017 Jun;37(6):3475-3483
pubmed: 28498474
Fish Shellfish Immunol. 2019 Sep;92:746-755
pubmed: 31279081
Onco Targets Ther. 2019 Dec 09;12:10693-10701
pubmed: 31849481
Int J Mol Sci. 2017 Sep 08;18(9):
pubmed: 28885545
Nat Rev Mol Cell Biol. 2016 Apr;17(4):205-11
pubmed: 26908011
Cell Death Dis. 2020 Feb 24;11(2):145
pubmed: 32094325
Cell Death Dis. 2020 Jan 6;11(1):18
pubmed: 31907361
Pathol Res Pract. 2019 Dec;215(12):152688
pubmed: 31727503
Adv Drug Deliv Rev. 2013 Mar;65(3):342-7
pubmed: 22776312
Cell Mol Biol (Noisy-le-grand). 2018 Aug 30;64(11):31-35
pubmed: 30213286
Cancer Res. 2019 Dec 1;79(23):5907-5914
pubmed: 31434645
Onco Targets Ther. 2018 Jun 21;11:3637-3647
pubmed: 29950867
Am J Cancer Res. 2019 Apr 01;9(4):630-643
pubmed: 31105992
Biochem Biophys Res Commun. 2019 Aug 13;516(1):102-111
pubmed: 31200957
DNA Cell Biol. 2015 Nov;34(11):692-700
pubmed: 26355845
Cancer Sci. 2018 Oct;109(10):3080-3092
pubmed: 30098109
Mol Ther. 2019 Mar 6;27(3):518-530
pubmed: 30692017
Cancer Sci. 2020 Mar;111(3):881-890
pubmed: 31883420
Mol Cancer. 2018 Apr 7;17(1):79
pubmed: 29626935
Mol Cancer. 2019 Jan 9;18(1):6
pubmed: 30626395
Mol Cancer. 2019 Oct 29;18(1):150
pubmed: 31665067
Mol Ther Nucleic Acids. 2020 Mar 6;19:384-392
pubmed: 31887549
J Clin Oncol. 2018 Jan 10;36(2):188-193
pubmed: 29220289
Cell Cycle. 2019 Jun;18(11):1281-1291
pubmed: 31116090
Med Sci Monit. 2019 Jun 29;25:4819-4830
pubmed: 31254341
Eur Rev Med Pharmacol Sci. 2020 Aug;24(15):7922
pubmed: 32767315